Literature DB >> 29151584

Towards 'off-the-shelf' genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells.

N Or-Geva1, R Gidron-Budovsky1, L Radomir1, Y Edelstein1, A K Singh1, R Sidlik-Muskatel1, E Ophir1, E Bachar-Lustig1, Y Reisner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29151584     DOI： 10.1038/leu.2017.332

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

2.  Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Authors:  Arnab Ghosh; Melody Smith; Scott E James; Marco L Davila; Enrico Velardi; Kimon V Argyropoulos; Gertrude Gunset; Fabiana Perna; Fabiana M Kreines; Emily R Levy; Sophie Lieberman; Hillary V Jay; Andrea Z Tuckett; Johannes L Zakrzewski; Lisa Tan; Lauren F Young; Kate Takvorian; Jarrod A Dudakov; Robert R Jenq; Alan M Hanash; Ana Carolina F Motta; George F Murphy; Chen Liu; Andrea Schietinger; Michel Sadelain; Marcel R M van den Brink
Journal:  Nat Med       Date:  2017-01-09       Impact factor: 53.440

3.  Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Michael Hudecek; Barbara Pender; Emily Robinson; Reed Hawkins; Colette Chaney; Sindhu Cherian; Xueyan Chen; Lorinda Soma; Brent Wood; Daniel Li; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

Review 4.  Challenges and opportunities of allogeneic donor-derived CAR T cells.

Authors:  Yinmeng Yang; Elad Jacoby; Terry J Fry
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

5.  Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.

Authors:  Laurent Poirot; Brian Philip; Cécile Schiffer-Mannioui; Diane Le Clerre; Isabelle Chion-Sotinel; Sophie Derniame; Pierrick Potrel; Cécile Bas; Laetitia Lemaire; Roman Galetto; Céline Lebuhotel; Justin Eyquem; Gordon Weng-Kit Cheung; Aymeric Duclert; Agnès Gouble; Sylvain Arnould; Karl Peggs; Martin Pule; Andrew M Scharenberg; Julianne Smith
Journal:  Cancer Res       Date:  2015-07-16       Impact factor: 12.701

6.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Authors:  James N Kochenderfer; Robert P T Somerville; Tangying Lu; Victoria Shi; Adrian Bot; John Rossi; Allen Xue; Stephanie L Goff; James C Yang; Richard M Sherry; Christopher A Klebanoff; Udai S Kammula; Marika Sherman; Arianne Perez; Constance M Yuan; Tatyana Feldman; Jonathan W Friedberg; Mark J Roschewski; Steven A Feldman; Lori McIntyre; Mary Ann Toomey; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

Review 7.  Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Authors:  Isabelle Rivière; Michel Sadelain
Journal:  Mol Ther       Date:  2017-04-26       Impact factor: 11.454

8.  Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.

Authors:  Eran Ophir; Noga Or-Geva; Irina Gurevich; Orna Tal; Yaki Eidelstein; Elias Shezen; Raanan Margalit; Assaf Lask; Guy Shakhar; David Hagin; Esther Bachar-Lustig; Shlomit Reich-Zeliger; Andreas Beilhack; Robert Negrin; Yair Reisner
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

Review 9.  The Principles of Engineering Immune Cells to Treat Cancer.

Authors:  Wendell A Lim; Carl H June
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

10.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

Authors:  Conrad Russell Y Cruz; Kenneth P Micklethwaite; Barbara Savoldo; Carlos A Ramos; Sharon Lam; Stephanie Ku; Oumar Diouf; Enli Liu; A John Barrett; Sawa Ito; Elizabeth J Shpall; Robert A Krance; Rammurti T Kamble; George Carrum; Chitra M Hosing; Adrian P Gee; Zhuyong Mei; Bambi J Grilley; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Catherine M Bollard; Gianpietro Dotti
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113
View more
  1 in total

1.  Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.

Authors:  Susan Prockop; Ekaterina Doubrovina; Stephanie Suser; Glenn Heller; Juliet Barker; Parastoo Dahi; Miguel A Perales; Esperanza Papadopoulos; Craig Sauter; Hugo Castro-Malaspina; Farid Boulad; Kevin J Curran; Sergio Giralt; Boglarka Gyurkocza; Katharine C Hsu; Ann Jakubowski; Alan M Hanash; Nancy A Kernan; Rachel Kobos; Guenther Koehne; Heather Landau; Doris Ponce; Barbara Spitzer; James W Young; Gerald Behr; Mark Dunphy; Sofia Haque; Julie Teruya-Feldstein; Maria Arcila; Christine Moung; Susan Hsu; Aisha Hasan; Richard J O'Reilly
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.